AAPGV Ascentage: Year-over-year earnings per share growth for the last twelve months
Ascentage Pharma Group (AAPGV) minimizes scientific threats by developing treatments for solid tumors and leukemia. On GURU.Markets, the quarterly earnings per share trend demonstrates operational resilience, where 0.00 captures the current value of the indicator. Patents for apoptosis inhibitors create a powerful barrier to entry, despite stringent FDA oversight. However, international research costs are driving losses and delaying monetization.
Summary analytical data breakdowns for Ascentage Pharma Group (AAPGV)
- share price and consensus valuation forecast:
- company stock capitalization data:
- book capitalization data:
- business debt structure and liquidity details:
Debt to Equity Ascentage Pharma Group|AAPGV - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital Ascentage Pharma Group International|AAPGV - Company Total Debt|Debts to Book Capitalization Ascentage Pharma Group Ltd|AAPGV - Long-Term Debt|Company Short-Term Debt Ascentage Pharma|Quick Liquidity Indicator ascentage.com
- earnings and valuation multiples indicators:
AAPGV - Profit After Payment of Taxes|Projected Future Earnings Ascentage Pharma Group|AAPGV - P/E Multiple|Forward P/E Multiple Ascentage|AAPGV - Price to Net Income Growth Ratio|EV/EBITDA Multiple Ascentage Pharma Group Ltd|AAPGV - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Ascentage Pharma|AAPGV - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months ascentage.com|AAPGV - Earnings per share trend in current year|Earnings growth forecast for next year Ascentage Pharma Group
- sales volume and revenue indicators:
Basic company analysis:ascentage.com - AAPGV
The efficiency of climate control during the delivery of oncology drugs directly impacts the margins of Ascentage Pharma Group (AAPGV), which is reflected in the rate of change of net earnings per share. By analyzing quarterly EPS dynamics, an investor assesses the growth rate of profit relative to the previous period, where a stable upward trend confirms operational resilience, while sharp drawdowns signal risks of overpaying for the asset.
Analysis of competing companies
ONC: Quarterly EPS earnings growth|Halozyme Inc. - Year-over-year earnings per one share growth for the last 12 months|RVMD (Revolution Medicines Inc) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Ascentage Pharma Group AAPG|Quarterly EPS earnings growth CGON|Quarterly EPS earnings growth UroGen Pharma Ltd (URGN)|Quarterly EPS earnings growth BCAX (Bicara Corp)|Personalis Genomics (PSNL) - Earnings per share growth in annualized terms for the last twelve months|Erasca Oncology - Quarterly EPS earnings growth|DCTH: Year-over-year earnings per share growth for the last twelve months|YMAB: Quarterly EPS earnings growth|Aura Bio (AURA) - Quarterly EPS earnings growth|CADL (Candel Therapeutics Inc.) - Quarterly EPS earnings growth|ARAY: Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months SLS (SELLAS Life Sciences Group, Inc.)|Year-over-year earnings per share growth rate for the last twelve months ACTU|Citius Oncology - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months HURA|TARA: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Fate Pharma|Aadi Bioscience Inc (WHWK) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months TScan (TCRX)|Year-over-year net earnings per share growth for the last 12 months CSBR|xbiotech.com (XBIT) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months cel-sci.com (CVM)|OSTX - Earnings per share growth in annualized terms for the last twelve months|Radiopharm Theranostics - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months ARTV|ANL - Year-over-year earnings per share growth for the last twelve months|VERU - Quarterly EPS earnings growth|Tempest Therapeutics, Inc. (TPST) - Year-over-year earnings per share growth for the last twelve months|XLO: Year-over-year earnings per share growth rate for the last twelve months|RENB (Renovaro Biosciences) - Quarterly EPS earnings growth|MURA: Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months KAPA (Kairos Pharma Ltd)|Year-over-year earnings per share growth rate for the last twelve months OKUR|CytoMed Therapeutics Limited - Year-over-year net earnings per share growth for the last 12 months|CRIS: Year-over-year earnings per share growth for the last 12 months|APLM - Year-over-year earnings per share growth for the last twelve months|THAR - Quarterly EPS earnings growth|ADVB: Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months GNPX|CLDI (Calidi Biotherapeutics, Inc.) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months SBFM|Quarterly EPS earnings growth XBIO|Year-over-year net earnings per share growth for the last 12 months Salarius Pharmaceuticals SLRX|Quarterly EPS earnings growth PPBT (Purple Biotech Ltd)|AONC - Year-over-year net earnings per share growth for the last 12 months|BGNE: Year-over-year net earnings per share growth for the last 12 months|Year-over-year net earnings per share change for the last twelve months Checkpoint Therapeutics, Inc CKPT|ELEV: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months iCAD Inc. (ICAD)|IKNA (Ikena) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Notable Labs (NTBL)|Quarterly EPS earnings growth VIRX|Year-over-year net earnings per share growth for the last 12 months MorphoSys Corporation MOR|NAYA Biosciences - Year-over-year net earnings per share growth for the last 12 months
